Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XY03-EA tablets for acute ischemic stroke
CTR20261085Phase 3Active
- Sponsor
- Yiling Pharmaceutical
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing XY03-EA with Placebo comparator (2 arms). Primary endpoint: Proportion of participants with modified Rankin Scale score 0 to 1 at day 90. Started May 2026; status: active.
02
Drugs
XY03-EA
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20261085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261085.